Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Advances in Therapy|November 21, 2023
Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort StudyKepeng Lu, Qian-Qian Liao, Ke-Wei Zhu, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|May 31, 2007
[Effect of hypoxic radiosensitizer sodium glycididazole on long-term result of radiotherapy for nasopharyngeal carcinoma]Meng-Zhong Liu, Li-Ru He, Tai-Xiang Lu, et al.
The Lancet. Oncology|December 14, 2011
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trialLei Chen, Chao-Su Hu, Xiao-Zhong Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2017
Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trialLei Chen, Chao-Su Hu, Xiao-Zhong Chen, et al.
Scientific Reports|June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
International Journal of Cancer|January 8, 2019
Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trialWen-Fei Li, Nian-Yong Chen, Ning Zhang, et al.
The Lancet. Oncology|October 1, 2016
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trialYing Sun, Wen-Fei Li, Nian-Yong Chen, et al.
Hepatology (Baltimore, Md.)|February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stagesDa-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer|June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter StudyDa-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Liver Cancer|January 19, 2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)Liang Ma, Da-Long Yang, Teng-Meng Zhong, et al.
Pageof 16